The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1338
Another Once-Daily Formulation of Tramadol (Ryzolt)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved tramadol hydrochloride extended-release (Ryzolt – Purdue) for treatment of moderate to moderately severe chronic pain in adults. Tramadol is already available in another extended-release formulation (Ultram ER) and in immediate-release tablets alone (Ultram, and others) and combined with acetaminophen (Ultracet, and others).

ANALGESIC ACTIVITY — Tramadol is a weak opioid agonist that also inhibits serotonin and norepinephrine reuptake; it is not scheduled as a controlled substance by the FDA. Tramadol 100 mg is about as effective for pain as aspirin 650 mg plus codeine 60 mg.1

PHARMACOKINETICS — Tramadol is converted by CYP2D6 to an active metabolite, O-desmethyltramadol, which has a much higher affinity than the parent drug for mu-opioid receptors. Studies in healthy volunteers found that serum concentrations ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Once-Daily Formulation of Tramadol (Ryzolt)
Article code: 1338c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian